292 related articles for article (PubMed ID: 37014414)
1. Repurposing drugs against Alzheimer's disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?
Leßmann V; Kartalou GI; Endres T; Pawlitzki M; Gottmann K
J Neural Transm (Vienna); 2023 Aug; 130(8):1003-1012. PubMed ID: 37014414
[TBL] [Abstract][Full Text] [Related]
2. Anti-Inflammatory Treatment with FTY720 Starting after Onset of Symptoms Reverses Synaptic Deficits in an AD Mouse Model.
Kartalou GI; Salgueiro-Pereira AR; Endres T; Lesnikova A; Casarotto P; Pousinha P; Delanoe K; Edelmann E; Castrén E; Gottmann K; Marie H; Lessmann V
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255764
[TBL] [Abstract][Full Text] [Related]
3. Modulatory Effects of Fingolimod (FTY720) on the Expression of Sphingolipid Metabolism-Related Genes in an Animal Model of Alzheimer's Disease.
Jęśko H; Wencel PL; Lukiw WJ; Strosznajder RP
Mol Neurobiol; 2019 Jan; 56(1):174-185. PubMed ID: 29687345
[TBL] [Abstract][Full Text] [Related]
4. Beneficial Effects of Fingolimod in Alzheimer's Disease: Molecular Mechanisms and Therapeutic Potential.
Angelopoulou E; Piperi C
Neuromolecular Med; 2019 Sep; 21(3):227-238. PubMed ID: 31313064
[TBL] [Abstract][Full Text] [Related]
5. Fingolimod Rescues Memory and Improves Pathological Hallmarks in the 3xTg-AD Model of Alzheimer's Disease.
Fagan SG; Bechet S; Dev KK
Mol Neurobiol; 2022 Mar; 59(3):1882-1895. PubMed ID: 35031916
[TBL] [Abstract][Full Text] [Related]
6. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis.
Roy R; Alotaibi AA; Freedman MS
CNS Drugs; 2021 Apr; 35(4):385-402. PubMed ID: 33797705
[TBL] [Abstract][Full Text] [Related]
7. Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation.
Miguez A; García-Díaz Barriga G; Brito V; Straccia M; Giralt A; Ginés S; Canals JM; Alberch J
Hum Mol Genet; 2015 Sep; 24(17):4958-70. PubMed ID: 26063761
[TBL] [Abstract][Full Text] [Related]
8. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives.
Bravo GÁ; Cedeño RR; Casadevall MP; Ramió-Torrentà L
Cells; 2022 Jun; 11(13):. PubMed ID: 35805142
[TBL] [Abstract][Full Text] [Related]
9. Dual dose-dependent effects of fingolimod in a mouse model of Alzheimer's disease.
Carreras I; Aytan N; Choi JK; Tognoni CM; Kowall NW; Jenkins BG; Dedeoglu A
Sci Rep; 2019 Jul; 9(1):10972. PubMed ID: 31358793
[TBL] [Abstract][Full Text] [Related]
10. The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod.
Patmanathan SN; Yap LF; Murray PG; Paterson IC
J Cell Mol Med; 2015 Oct; 19(10):2329-40. PubMed ID: 26171944
[TBL] [Abstract][Full Text] [Related]
11. The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination.
Baker D; Forte E; Pryce G; Kang AS; James LK; Giovannoni G; Schmierer K
Mult Scler Relat Disord; 2023 Jan; 69():104425. PubMed ID: 36470168
[TBL] [Abstract][Full Text] [Related]
12. Neurorestorative effect of FTY720 in a rat model of Alzheimer's disease: comparison with memantine.
Hemmati F; Dargahi L; Nasoohi S; Omidbakhsh R; Mohamed Z; Chik Z; Naidu M; Ahmadiani A
Behav Brain Res; 2013 Sep; 252():415-21. PubMed ID: 23777795
[TBL] [Abstract][Full Text] [Related]
13. FTY720 Attenuates Infection-Induced Enhancement of Aβ Accumulation in APP/PS1 Mice by Modulating Astrocytic Activation.
McManus RM; Finucane OM; Wilk MM; Mills KHG; Lynch MA
J Neuroimmune Pharmacol; 2017 Dec; 12(4):670-681. PubMed ID: 28620801
[TBL] [Abstract][Full Text] [Related]
14. From the Molecular Mechanism to Pre-clinical Results: Anti-epileptic Effects of Fingolimod.
Paudel YN; Angelopoulou E; Piperi C; Gnatkovsky V; Othman I; Shaikh MF
Curr Neuropharmacol; 2020; 18(11):1126-1137. PubMed ID: 32310049
[TBL] [Abstract][Full Text] [Related]
15. Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects.
Chun J; Giovannoni G; Hunter SF
Drugs; 2021 Feb; 81(2):207-231. PubMed ID: 33289881
[TBL] [Abstract][Full Text] [Related]
16. Lipid transporter Spns2 promotes microglia pro-inflammatory activation in response to amyloid-beta peptide.
Zhong L; Jiang X; Zhu Z; Qin H; Dinkins MB; Kong JN; Leanhart S; Wang R; Elsherbini A; Bieberich E; Zhao Y; Wang G
Glia; 2019 Mar; 67(3):498-511. PubMed ID: 30484906
[TBL] [Abstract][Full Text] [Related]
17. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
McGinley MP; Cohen JA
Lancet; 2021 Sep; 398(10306):1184-1194. PubMed ID: 34175020
[TBL] [Abstract][Full Text] [Related]
18. Fingolimod Affects Transcription of Genes Encoding Enzymes of Ceramide Metabolism in Animal Model of Alzheimer's Disease.
Jęśko H; Wencel PL; Wójtowicz S; Strosznajder J; Lukiw WJ; Strosznajder RP
Mol Neurobiol; 2020 Jun; 57(6):2799-2811. PubMed ID: 32356173
[TBL] [Abstract][Full Text] [Related]
19. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Brinkmann V
Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
[TBL] [Abstract][Full Text] [Related]
20. Sphingosine-1-phosphate signaling: A novel target for simultaneous adjuvant treatment of triple negative breast cancer and chemotherapy-induced neuropathic pain.
Singh SK; Spiegel S
Adv Biol Regul; 2020 Jan; 75():100670. PubMed ID: 31708456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
